Proposed mechanisms include PD-L1 upregulation via multiple signaling pathways, modulation of immune cells within the tumor microenvironment, and gut microbiota alterations affecting PD-1/PD-L1 inhibitor efficacy.<h4>Conclusion</h4>H. This evidence concerns the gene CD274 and neoplasm.